Eurocell (ECEL) Share Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eurocell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ECEL shares.
View ECEL analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month price objectives for Eurocell's stock. Their ECEL share price forecasts range from GBX 250 to GBX 250. On average, they anticipate the company's stock price to reach GBX 250 in the next twelve months. This suggests a possible upside of 113.7% from the stock's current price.
View analysts price targets for ECEL or view top-rated stocks among Wall Street analysts.

Eurocell's stock was trading at GBX 147.50 at the start of the year. Since then, ECEL shares have decreased by 20.7% and is now trading at GBX 117.
View the best growth stocks for 2023 here.

Eurocell plc (LON:ECEL) released its earnings results on Thursday, August, 1st. The company reported $8.70 EPS for the quarter. Eurocell had a net margin of 5.17% and a trailing twelve-month return on equity of 19.90%.

Eurocell declared a dividend on Thursday, March 16th. Investors of record on Thursday, April 20th will be given a dividend of GBX 7.20 per share on Wednesday, May 17th. This represents a dividend yield of 5.2%. The ex-dividend date of this dividend is Thursday, April 20th. This is a boost from the stock's previous dividend of GBX 3.50. The official announcement can be viewed at this link.
Read our dividend analysis for ECEL.

Eurocell (LON:ECEL) pays an annual dividend of GBX 11 per share and currently has a dividend yield of 9.30%. ECEL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 5,789.47%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for ECEL.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eurocell investors own include Dynavax Technologies (DVAX), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB), EQTEC (EQT) and Exact Sciences (EXAS).

Eurocell trades on the London Stock Exchange (LON) under the ticker symbol "ECEL."

Shares of ECEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of ECEL stock can currently be purchased for approximately GBX 117.

Eurocell (LON:ECEL) has a market capitalization of £131.15 million and generates £381.20 million in revenue each year. The company earns £22 million in net income (profit) each year or GBX 0.19 on an earnings per share basis.

The company employs 2,000 workers across the globe.

Eurocell's mailing address is FAIRBROOK HO CLOVER NOOK RD, ALFRETON, DE55 4RF, United Kingdom. The official website for the company is www.eurocell.co.uk. The company can be reached via phone at +44-1773-830585.